Compare Atlassian Corporation PLC (TEAM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Zoetis Inc — how do they compare? Atlassian Corporation PLC trades at $203.42 (market cap $51.53B), while Zoetis Inc trades at $74.24 (market cap $30.20B). The key difference: Atlassian Corporation PLC is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 64 Days and Zoetis Inc for 70 Days on average.
| TEAM | ZTS | |
|---|---|---|
Market Cap | $51.53B | $30.20B |
Volume | 2,904,511 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $203.57 | $147.53 |
52-Week Low | $57.15 | $69.09 |
Typical Hold Time | 64 Days | 70 Days |
Enterprise Value | $51.52B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $2.8B in 2022 to $5.22B in 2025, though net margins remain negative. Recent earnings beats and AI-driven cloud adoption provide momentum, with the current price near resistance at $196.
Outlook remains positive given robust cloud growth and AI integration, but high valuations and persistent losses pose risks. Wall Street consensus is strongly bullish with 30 buy ratings and a $191.16 target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in the enterprise software space.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed earnings performance, having beaten estimates in Q2 2026 but missing in Q1. Despite recent headwinds in U.S. companion animal sales, the company maintains strong profitability with 71.67% gross margins and 27.69% net income margins. Analyst consensus remains positive with a $87.33 price target, though technical indicators suggest near-term pressure with support at $70-$71.
Zoetis presents a compelling value opportunity with attractive valuation multiples (P/E 11.92, EV/EBITDA 9.4) and robust fundamentals, though near-term risks include competitive pressures in pet medications and weakening U.S. veterinary clinic traffic. The company's international and livestock segments show resilience, supporting long-term growth potential despite current market skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
